Cynosure Company Profile (NASDAQ:CYNO)

About Cynosure (NASDAQ:CYNO)

Cynosure logoCynosure, Inc. develops, manufactures and markets aesthetic treatment systems that enable plastic surgeons, dermatologists and other medical practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, reduce fat through laser lipolysis, reduce cellulite, clear nails infected by toe fungus, ablate sweat glands and improve women's health. The Company also markets radiofrequency (RF), energy-sourced medical devices for surgical applications, such as facial plastic and general surgery, gynecology, ear, nose, and throat procedures, ophthalmology, oral and maxillofacial surgery, podiatry and proctology. The Company sells its products globally under the Cynosure, Palomar, ConBio and Ellman brand names. Its product portfolio includes single energy source systems, as well as workstations that incorporate two or more different types of lasers or light-based technologies.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Advanced Medical Equipment & Technology
  • Sub-Industry: Health Care Equipment
  • Symbol: NASDAQ:CYNO
  • CUSIP: 23257720
  • Web:
Average Prices:
  • 50 Day Moving Avg: $62.47
  • 200 Day Moving Avg: $50.89
  • 52 Week Range: $39.90 - $66.65
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 32.50
  • P/E Growth: 0.00
  • Net Margins: 0.70%
  • Return on Equity: 0.75%
  • Return on Assets: 0.59%
  • Debt-to-Equity Ratio: 0.04%
  • Current Ratio: 3.28%
  • Quick Ratio: 2.54%
  • Average Volume: 1.17 million shs.
  • Beta: 1.65

Frequently Asked Questions for Cynosure (NASDAQ:CYNO)

What is Cynosure's stock symbol?

Cynosure trades on the NASDAQ under the ticker symbol "CYNO."

How were Cynosure's earnings last quarter?

Cynosure, Inc. (NASDAQ:CYNO) announced its quarterly earnings results on Tuesday, July, 26th. The company reported $0.36 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.29 by $0.07. The business earned $110.30 million during the quarter, compared to analyst estimates of $101.31 million. Cynosure had a return on equity of 0.75% and a net margin of 0.70%. The firm's revenue was up 31.8% on a year-over-year basis. During the same period in the previous year, the company earned $0.30 EPS. View Cynosure's Earnings History.

Where is Cynosure's stock going? Where will Cynosure's stock price be in 2017?

7 brokers have issued 1-year target prices for Cynosure's shares. Their predictions range from $40.00 to $66.00. On average, they anticipate Cynosure's stock price to reach $58.33 in the next year. View Analyst Ratings for Cynosure.

Who are some of Cynosure's key competitors?

How do I buy Cynosure stock?

Shares of Cynosure can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cynosure's stock price today?

One share of Cynosure stock can currently be purchased for approximately $65.97.

MarketBeat Community Rating for Cynosure (NASDAQ CYNO)
Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  219 (Vote Outperform)
Underperform Votes:  113 (Vote Underperform)
Total Votes:  332
MarketBeat's community ratings are surveys of what our community members think about Cynosure and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Cynosure (NASDAQ:CYNO) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Hold Ratings, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.57)
Consensus Price Target: $58.33 (11.58% downside)
Consensus Price Target History for Cynosure (NASDAQ:CYNO)
Price Target History for Cynosure (NASDAQ:CYNO)
Analysts' Ratings History for Cynosure (NASDAQ:CYNO)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
3/28/2017AegisReiterated RatingHold$66.00N/AView Rating Details
2/16/2017Northland SecuritiesReiterated RatingOutperform$60.00N/AView Rating Details
2/14/2017Northcoast ResearchUpgradeSell -> NeutralN/AView Rating Details
2/14/2017Maxim GroupDowngradeBuy -> Hold$66.00N/AView Rating Details
10/28/2016Leerink SwannReiterated RatingOutperform$63.00 -> $60.00N/AView Rating Details
10/26/2016Stifel NicolausReiterated RatingBuy$62.00 -> $58.00N/AView Rating Details
10/24/2016Brean CapitalReiterated RatingBuyN/AView Rating Details
(Data available from 10/17/2015 forward)


Earnings History for Cynosure (NASDAQ:CYNO)
Earnings by Quarter for Cynosure (NASDAQ:CYNO)
Earnings History by Quarter for Cynosure (NASDAQ CYNO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/7/2017Q416$0.41$0.44$119.97 million$122.10 millionViewListenView Earnings Details
10/25/2016Q316$0.28$0.29$101.11 million$106.40 millionViewListenView Earnings Details
7/26/2016Q216$0.29$0.36$101.31 million$110.30 millionViewListenView Earnings Details
4/26/2016Q116$0.14$0.19$85.78 million$94.70 millionViewListenView Earnings Details
2/9/2016Q415$0.36$0.42$95.01 million$102.40 millionViewListenView Earnings Details
10/27/2015Q315$0.18$0.21$76.68 million$78.40 millionViewListenView Earnings Details
7/28/2015Q215$0.27$0.30$82.71 million$83.70 millionViewListenView Earnings Details
5/5/2015Q1$0.17$0.15$70.87 million$74.90 millionViewListenView Earnings Details
2/10/2015Q414$0.39$0.36$83.01 million$86.30 millionViewListenView Earnings Details
10/28/2014Q314$0.24$0.25$69.94 million$71.50 millionViewListenView Earnings Details
7/29/2014Q214$0.30$0.32$71.15 million$72.60 millionViewListenView Earnings Details
5/6/2014Q1$0.23$0.19$64.70 million$62.00 millionViewListenView Earnings Details
2/12/2014Q413$0.19$0.39$67.80 million$74.50 millionViewListenView Earnings Details
10/29/2013Q313$0.19$0.23$61.60 million$60.70 millionViewListenView Earnings Details
7/31/2013Q2 2013$0.20$0.29$46.96 million$50.09 millionViewListenView Earnings Details
4/30/2013Q1 2013$0.13$0.12$38.51 million$10.70 millionViewListenView Earnings Details
2/12/2013Q4 2012$0.23$0.27$40.98 million$47.70 millionViewListenView Earnings Details
10/23/2012$0.12$0.25ViewN/AView Earnings Details
7/24/2012$0.12$0.20ViewN/AView Earnings Details
5/1/2012($0.02)$0.06ViewN/AView Earnings Details
2/14/2012$0.05$0.08ViewN/AView Earnings Details
10/25/2011$0.04($0.06)ViewN/AView Earnings Details
5/3/2011($0.05)($0.15)ViewN/AView Earnings Details
2/15/2011($0.03)($0.06)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Cynosure (NASDAQ:CYNO)
2017 EPS Consensus Estimate: $1.63
2018 EPS Consensus Estimate: $2.02
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$0.23$0.26$0.24
Q2 20173$0.40$0.44$0.43
Q3 20173$0.38$0.42$0.40
Q4 20173$0.51$0.61$0.57
Q1 20181$0.34$0.34$0.34
Q2 20181$0.51$0.51$0.51
Q3 20181$0.50$0.50$0.50
Q4 20181$0.67$0.67$0.67
(Data provided by Zacks Investment Research)


Dividend History for Cynosure (NASDAQ:CYNO)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Cynosure (NASDAQ:CYNO)
Insider Ownership Percentage: 2.90%
Insider Trades by Quarter for Cynosure (NASDAQ:CYNO)
Institutional Ownership by Quarter for Cynosure (NASDAQ:CYNO)
Insider Trades by Quarter for Cynosure (NASDAQ:CYNO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/22/2016Douglas J DelaneyVPSell7,875$45.00$354,375.00View SEC Filing  
11/22/2016Michael R DavinChairmanSell16,284$45.00$732,780.00View SEC Filing  
8/30/2016Brian M BarefootDirectorSell21,000$51.66$1,084,860.00View SEC Filing  
8/15/2016Michael R DavinChairmanSell12,062$53.35$643,507.70View SEC Filing  
8/15/2016Timothy W BakerCFOSell5,834$53.35$311,243.90View SEC Filing  
8/11/2016Michael R DavinChairmanSell4,222$53.18$224,525.96View SEC Filing  
8/11/2016Timothy W BakerCFOSell2,041$53.19$108,560.79View SEC Filing  
5/13/2016Douglas J DelaneyVPSell12,299$46.60$573,133.40View SEC Filing  
5/13/2016Michael R DavinCEOSell26,271$46.59$1,223,965.89View SEC Filing  
5/13/2016Timothy W BakerCFOSell12,451$46.60$580,216.60View SEC Filing  
4/18/2016Douglas J DelaneyVPSell15,890$45.01$715,208.90View SEC Filing  
4/18/2016Michael R DavinCEOSell74,729$45.31$3,385,970.99View SEC Filing  
4/18/2016Timothy W BakerCFOSell14,008$45.02$630,640.16View SEC Filing  
4/14/2016Douglas J DelaneyVPSell24,488$45.02$1,102,449.76View SEC Filing  
4/14/2016Michael R DavinCEOSell61,377$45.01$2,762,578.77View SEC Filing  
4/14/2016Timothy W BakerCFOSell39,857$45.02$1,794,362.14View SEC Filing  
4/13/2016Michael R DavinCEOSell72$45.00$3,240.00View SEC Filing  
4/6/2016Douglas J DelaneyVPSell4,408$45.08$198,712.64View SEC Filing  
4/6/2016Michael R DavinCEOSell4,869$45.11$219,640.59View SEC Filing  
4/6/2016Timothy W BakerCFOSell4,413$45.08$198,938.04View SEC Filing  
4/4/2016Douglas J DelaneyVPSell66,626$45.47$3,029,484.22View SEC Filing  
4/4/2016Michael R DavinCEOSell66,259$45.61$3,022,072.99View SEC Filing  
4/4/2016Timothy W BakerCFOSell53,297$45.60$2,430,343.20View SEC Filing  
12/31/2015Michael R. DavinCEOSell200$45.00$9,000.00View SEC Filing  
12/31/2015Timothy W. BakerCFOSell100$45.00$4,500.00View SEC Filing  
6/1/2015Ettore V BiagioniDirectorSell24,000$36.25$870,000.00View SEC Filing  
5/20/2015Douglas J DelaneyVPSell89,000$38.01$3,382,890.00View SEC Filing  
5/20/2015Michael R DavinCEOSell151,000$38.07$5,748,570.00View SEC Filing  
4/23/2015Michael R DavinCEOSell6,991$33.04$230,982.64View SEC Filing  
4/10/2015Michael R DavinCEOSell44,677$33.01$1,474,787.77View SEC Filing  
4/9/2015Douglas J DelaneyVPSell28,335$33.01$935,338.35View SEC Filing  
4/9/2015Michael R DavinCEOSell70,000$32.00$2,240,000.00View SEC Filing  
4/8/2015Douglas J DelaneyVPSell45,000$32.00$1,440,000.00View SEC Filing  
1/9/2015Ettore V BiagioniDirectorSell12,000$30.09$361,080.00View SEC Filing  
12/2/2014Ettore V BiagioniDirectorSell2,500$28.00$70,000.00View SEC Filing  
11/24/2014Ettore V BiagioniDirectorSell5,000$27.28$136,400.00View SEC Filing  
11/5/2013Marina HatsopoulosDirectorBuy3,000$22.60$67,800.00View SEC Filing  
9/5/2012Douglas J DelaneyVPSell16,904$27.65$467,395.60View SEC Filing  
9/5/2012Michael R DavinCEOSell16,770$27.65$463,690.50View SEC Filing  
9/5/2012Timothy W BakerCFOSell16,854$27.65$466,013.10View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Cynosure (NASDAQ:CYNO)
Latest Headlines for Cynosure (NASDAQ:CYNO)
DateHeadline logo3 Plastic & Reconstructive Surgery Stocks Looking Good - Nasdaq - October 12 at 11:34 PM logo3 Plastic & Reconstructive Surgery Stocks Looking Good - October 11 at 7:12 PM logoCritical Review: Cynosure (CYNO) versus Intuitive Surgical (ISRG) - October 1 at 4:38 PM logoHologic (HOLX) Granted FDA 510(k) Clearance to Market SculpSure for Non-Invasive Body Contouring (Lipolysis) of the Submental Area - September 27 at 6:50 PM logoHologic Receives FDA 510(k) Clearance to Market SculpSure® for Non-Invasive ... - September 27 at 6:50 PM logoHologic Receives FDA 510(k) Clearance to Market SculpSure® for Non-Invasive Body Contouring (Lipolysis) of the Submental Area (Under the Chin) - September 27 at 6:50 PM logoCosmetic Procedures Market to Reach US$ 51.6 Billion by 2022 – Persistence Market Research - September 27 at 6:50 PM logoTrump's Pick for Federal Reserve's Top Regulator Just Won This Battle - September 8 at 6:07 PM logoCutera Strengthens Leadership Team with Two Key Executive Appointments - Nasdaq - August 21 at 10:26 PM logoGlobal Aesthetic Laser Market 2017-2023 - Leading Companies Cynosure, Lumenis, Cutera, Alma Lasers & Sciton - Research and Markets - August 19 at 4:57 PM logoGlobal Aesthetic Laser Market 2017-2023 - Leading Companies ... - Business Wire (press release) - August 18 at 5:44 PM logoAnalyzing Derma Sciences (DSCI) & Cynosure (CYNO) - August 3 at 8:29 AM logoHologic (HOLX) Q3 2017 Results - Earnings Call Transcript - August 2 at 11:37 PM logoHologic Announces Financial Results for Third Quarter of Fiscal 2017 - August 2 at 6:37 PM logoTrump's Wall Street Watchdogs to Shed Millions Invested in Banks - Bloomberg - July 25 at 5:42 PM logoWhat's in the Offing for Hologic (HOLX) in Q3 Earnings? - Nasdaq - July 24 at 10:46 AM logoMedical Aesthetics Market to Reach $19.4 Billion by 2023: P&S Market Research - July 19 at 11:56 PM logoHologic: Growth Cheaply Priced - Seeking Alpha - July 16 at 9:42 AM logoRevolving Door Spins Ex-Carlyle Deal-Maker Into Key Fed Role - July 12 at 11:27 PM logoTrump's Fed Nominee Has History of Benefiting From Bailouts - New York Times - July 12 at 6:24 PM logoHologic Receives Expanded FDA 510(k) Clearance to Market Cynosure's SculpSure ... - June 15 at 6:33 PM logoGlobal Cellulite Treatment Market - Industry Forecast to 2025 - Analysis By Treatment, End User & Geography - Research and Markets - June 8 at 5:39 PM logoGlobal Anti-Aging Market Size & Trends Will Reach $216.52 Billion by 2021: Zion Market Research - June 5 at 11:54 AM logoGlobal Medical Aesthetics Market to Reach $13 Billion by 2021 - Analysis By Product, End User & Region - Research and Markets - May 29 at 4:45 PM logoAsia-Pacific Aesthetic Lasers and Energy Devices Market Outlook to 2023 - May 16 at 4:39 PM logoMedical Aesthetic Devices Market - Middle East and North Africa Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024 - May 11 at 10:18 PM logoAesthetics Combination Therapy Market Revenues to Reach US$ 3.69 Bn by 2024 - Persistence Market Research - May 3 at 8:46 AM logoLiposuction Devices - Global Market Outlook (2016-2022) - April 27 at 5:10 PM logoTrump to Nominate Quarles for Fed's Top Regulatory Post, Source Says - April 18 at 12:07 PM logoSouth Korea Aesthetic Lasers and Energy Devices Market Outlook to 2023 - April 11 at 4:29 PM logoGermany Aesthetic Lasers and Energy Devices Market Outlook to 2023 - April 10 at 4:30 PM logoForm 4 CYNOSURE INC For: Mar 22 Filed by: Hatsopoulos Marina - - March 25 at 11:01 AM logoForm 4 CYNOSURE INC For: Mar 22 Filed by: Hatsopoulos Marina - March 24 at 9:55 PM logoForm SC 14D9/A CYNOSURE INC Filed by: CYNOSURE INC - March 24 at 4:53 PM logoDermatology Devices Market Worth $25 Billion by 2025 | CAGR: 12.7%: Grand View Research, Inc. - March 23 at 5:11 PM logoCYNOSURE INC Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure t - March 23 at 5:11 PM logoForm SC 14D9/A CYNOSURE INC Filed by: CYNOSURE INC - - March 4 at 2:49 AM logoCYNOSURE INC Files SEC form 10-K, Annual Report - March 1 at 1:14 PM logoCYNOSURE INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits - February 22 at 9:00 AM logoCYNOSURE, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe Believes the Acquisition by Hologic ... - Business Wire (press release) - February 18 at 8:08 AM logoCynosure Inc. (CYNO) Leaped To A New High After Purchased By Hologic - February 16 at 7:01 PM logoSHAREHOLDER ALERT: Brower Piven Commences An ... - Business Wire (press release) - February 16 at 2:00 PM logoHere's Why Cynosure, Inc. is Soaring Today - Motley Fool - February 16 at 2:00 PM logoHologic to Acquire Cynosure for $1.65 Billion - February 16 at 2:00 PM logoCYNOSURE INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Amendments to Articles of Inc. or Bylaws - February 14 at 10:27 PM logoCynosure Inc. (CYNO) Has Jumped To A New High After Bought By Hologic - February 14 at 5:25 PM logoCynosure's stock rockets after buyout deal with Hologic - February 14 at 5:25 PM logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Whether the Sale of Cynosure, Inc. for $66 Per Share is Fair to Shareholders - CYNO - February 14 at 5:25 PM logoHologic will snap up Westford-based Cynosure in $1.65B deal - February 14 at 5:25 PM logoHologic to buy Cynosure to expand into medical aesthetics - February 14 at 5:25 PM



Cynosure (CYNO) Chart for Tuesday, October, 17, 2017

This page was last updated on 10/17/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.